Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -39%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
SAMSUNG PHARM.
001360 · KOSPI₩1,319-0.83%
2026-09-04 closeSAMSUNG PHARM. last closed at ₩1,319 (-0.83%) on 2026-09-04. Listed on KOSPI; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
C+
Overall: 건강관리 190/291 · top 65%
Factor composite · relative position in sector
PER — · PBR 1.17 — own-history percentile 45/100 · 82/100
Open self-history band
PER45/100
PBR82/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Grey zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 2.56
Distress
Grey
Safe
- Altman Z''
- 2.56
- Beneish M-Score
- -1.35
- Sloan accrual
- 2.49%
Statistical manipulation-risk signal
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
4/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score4/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 170 of 287, share 0.1%.
170 / 2870.1%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6삼성제약0.1%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 13.9
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -36.3%
- Interest coverage
- -69.5x
- Return on equity (ROE)
- -13.3%
Operating margin −5pp
Operating lossInterest coverageBase -69.5x adverse case -79.1x
Return on equity (ROE)Base -13.3% adverse case -17.5%
Revenue −15%
Interest coverage riskInterest coverageBase -69.5x adverse case -59.1x
Return on equity (ROE)Base -13.3% adverse case -13.1%
Interest rate +2pp
Interest coverage riskInterest coverageBase -69.5x adverse case -23.5x
Return on equity (ROE)Base -13.3% adverse case -15.8%
Interest coverage limit
Already below the limit by 36.8ppInterest coverage limit at an operating margin of 0.5%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Suppliers without disclosed amount
ZhuhaiUnited
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 젬백스10.47%2026-01-08 · 증감 0.00%p
- 제스트 신기술조합 제72호8.55%2025-08-22 · 증감 +8.55%p
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- 포니링크KRA064800 →
Shared holders: 젬백스
Connections
AI-extracted related companies · for reference
Suppliers
Competitors
셀트리온Price comovement r=0.23 (1 year)유한양행Price comovement r=0.18 (1 year)종근당Price comovement r=0.19 (1 year)한미약품Price comovement r=0.10 (1 year)대웅제약Price comovement r=0.11 (1 year)GC녹십자광동제약Price comovement r=0.19 (1 year)동아에스티Price comovement r=0.20 (1 year)JW중외제약Price comovement r=0.26 (1 year)동화약품Price comovement r=0.27 (1 year)일동제약Price comovement r=0.13 (1 year)대원제약Price comovement r=0.25 (1 year)
Same theme
Recent filings
SAMSUNG PHARM.'s latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About SAMSUNG PHARM.
- What technical signals does SAMSUNG PHARM. (001360) have?
- SAMSUNG PHARM. current technical signals: no active technical signal.
- Is SAMSUNG PHARM. a cup-and-handle pattern?
- No. SAMSUNG PHARM. has no valid cup-and-handle signal right now.
- What are SAMSUNG PHARM.'s financials and valuation?
- SAMSUNG PHARM.'s income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy